Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 19/20 | 0.56 |
| ▸ | AKT2 | P31751 | 19/20 | 0.56 |
| ▸ | AKT3 | Q9Y243 | 19/20 | 0.56 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.53 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.53 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2517506 | 1.00 | AKT1 (0.56) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL2517428 | 1.00 | AKT1 (0.56) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL2531668 | 0.80 | AKT1 (0.57) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL191257 | 0.78 | AKT1 (0.78) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL17029622 | 0.78 | AKT1 (0.78) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL191258 | 0.78 | AKT1 (0.78) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL22622567 | 0.76 | AKT1 (0.75) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL191788 | 0.76 | AKT1 (0.85) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL191789 | 0.76 | AKT1 (0.85) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL23532373 | 0.75 | RPS6KB1 (0.54) | AKT1AKT2AKT3RPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895566-B2 | 5H-cyclopenta[d]pyrimidines as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2014-11-25 | — | — | US | claimed |
| US-20130085135-A1 | 5H-CYCLOPENTA[D]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | GENENTECH, INC. (US) | 2013-04-04 | — | — | US | claimed |
| US-8329709-B2 | 5H-cyclopenta[D]pyrimidines as AKT protein kinase inhibitors | GENENTECH, INC. (US) | 2012-12-11 | — | — | US | claimed |
| US-20110251181-A1 | 5H-CYCLOPENTA[D]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | GENENTECH, INC. (US) | 2011-10-13 | — | — | US | claimed |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2022-09-20 | — | — | US | disclosed |
| US-20190183843-A9 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS, INC. (CA) | 2019-06-20 | — | — | US | disclosed |
| US-20190175541-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS, INC. (CA) | 2019-06-13 | — | — | US | disclosed |
| US-20180071244-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS INC (CA) | 2018-03-15 | — | — | US | disclosed |
| WO-2017075052-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS, INC. (CA) | 2017-05-04 | — | — | WO | disclosed |
| US-9328091-B2 | 5H-cyclopenta[d]pyrimidines as AKT protein kinase inhibitors | GENENTECH, INC. (US) | 2016-05-03 | — | — | US | disclosed |
| US-20150266852-A1 | 5H-CYCLOPENTA[d]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | GENENTECH, INC. | 2015-09-24 | — | — | US | disclosed |
| US-8895566-B2 | 5H-cyclopenta[d]pyrimidines as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2014-11-25 | — | — | US | disclosed |
| EP-2250155-B1 | 5H-CYCLOPENTA[D]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2013-07-03 | — | — | EP | disclosed |
| US-20130085135-A1 | 5H-CYCLOPENTA[D]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | GENENTECH, INC. (US) | 2013-04-04 | — | — | US | disclosed |
| US-8329709-B2 | 5H-cyclopenta[D]pyrimidines as AKT protein kinase inhibitors | GENENTECH, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20110251181-A1 | 5H-CYCLOPENTA[D]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | GENENTECH, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| EP-2250155-A1 | 5H-CYCLOPENTA[D]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009089462-A1 | 5H-CYCLOPENTA[D]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190175541-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DCK, CDC7, DNMT1 | AKT1 829/4885AKT2 1108/4885AKT3 791/4885 |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DCK, CDC7, DNMT1 | AKT1 829/4885AKT2 1108/4885AKT3 791/4885 |
| US-20180071244-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DCK, CDC7, DNMT1 | AKT1 829/4885AKT2 1108/4885AKT3 791/4885 |
| US-20190183843-A9 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DCK, CDC7, DNMT1 | AKT1 829/4885AKT2 1108/4885AKT3 791/4885 |
| US-20150266852-A1 | 5H-CYCLOPENTA[d]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | PIK3CA, AKT3, AKT2 | AKT1 7/4885AKT2 3/4885AKT3 2/4885 |
| US-20130085135-A1 | 5H-CYCLOPENTA[D]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | PIK3CA, AKT3, AKT2 | AKT1 7/4885AKT2 3/4885AKT3 2/4885 |
| US-20110251181-A1 | 5H-CYCLOPENTA[D]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | AKT3, PIK3CA, AKT2 | AKT1 5/4885AKT2 3/4885AKT3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.